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BUDD-CHIARI SYNDROME: SHUNT OR
TRANSPLANT?
ABSTRACT
Shaked, A., Goldstein, R.M., Klintmalm, G.B., Drazan, K., Husberg, B. and
Busuttil, R.W. (1992) Portosystemic shunt oersus orthotopic lioer transplantationfor
the Budd-Chiari Syndrome. Surgery, Gynecology & Obstetrics; 174: 453-459.
We have analyzed the indications and results of shunt operation versus orthotopic
liver transplantation (OLT) in 22 patients with Budd-Chiari syndrome (BCS). The
underlying cause of the syndrome was similar between the two groups and was
related to myeloproliferative disorders or the use of birth control, pills in 18 of 22
patients. The results of biopsies of the liver showed centrilobular congestion and
necrosis in all candidates who underwent shunting and the presence of fibrosis and
cirrhosis in the OLT candidates. The indications for shunts included symptoms
related to portal hypertension only and well-preserved synthetic hepatic function.
Ten patients were treated with 12 shunt procedures, including mesoatrial (eight
patients) and side to side portacaval shunt (four patients). Significant complications258 HPB INTERNATIONAL
after shunt procedure included fulminant (one of ten patients) and progressive (one
of ten patients) hepatic failure requiring urgent OLT; one death occurred because of
pulmonary sepsis. Indications for OLT were signs of end stage liver expressed by
severe portal hypertension and variceal bleeding (four of 14 patients), progressive
encephalopathy (seven of 14 patients) and poor synthetic function (bilirubin > 3
milligrams per deciliter in eight of 14 patients and albumin < 3.0 grams per liter, or
both, in ten of 14 patients). Fourteen patients were treated with 16 OLT, three
patients had retransplantation for primary nonfunction graft (two of 14 patients) or
chronic rejection (one of 14 patients). There were two early deaths in the group.
With a follow-up period between two months to five years, 12 of 14 patients
undergoing OLT are alive, fully functional and have normal liver function tests.
Seven of ten patients who had shunts are alive, six are able to maintain normal
activity and one has progressive end stage hepatic disease and is not a candidate for
OLT. However, the hepatic function continues progressively to be abnormal.
Various options are available for the treatment of the syndrome. Portosystemic
decompression is effective and should be considered at the early stage of the disease,
prior to the development of significant hepatic failure. However, few of the patients
will continue to have slow, but progressive hepatic failure and may require OLT.
The only effective treatment for end stage hepatic disease secondary to the BCS is
OLT.
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The Budd-Chiari Syndrome is fortunately uncommon as it affects relatively young
patients who present with abdominal pain, ascites, hepatomegaly and deteriorating
liver function. While mechanical outflow obstruction due to a vena-caval web,
stricture or malignancy may produce the syndrome all too often a hypercoagulable
state is responsible with myeloproliferative disorders such as polycythemia rubra
vera in more than half of the cases with systemic lupus nocturnal haemoglobinuria
and anti-thrombin III deficiency also implicated. The relative infrequency of such
patients and small numbers attending an individual centre makes effective evalu-
ation of treatment options difficult. The authors in their series outline the successes
of liver transplantation in treating the chronic Budd-Chiari Syndrome and compare
it with portal shunting. The European Liver Transplantation Registry currently
records that patients grafted with Budd-Chiari Syndrome since 1988 will achieve a 3
year survival of over 75% (92 patients).
However, the shortage of available organs and the need for long term immuno-
suppression rightly means that alternative options should always be initially
reviewed. Clearly late cases of Budd-Chiari Syndrome where there is advanced
fibrosis and portal hypertension with cirrhosis will not be benefited by hepatic
portal shunting and will probably require hepatic transplantation. However, in the
early acute cases where fibrinolytic therapy has been ineffectve then shunting
should be a clinical modality which is urgently reviewed. The development of
massive hepatic congestion in the Budd-Chiari Syndrome but preserved hepatic
function often can be resolved with adequate portal decompression by a porto-
caval shunt or alternatively a meso-atrial shunt when the cava is obliterated. TheHPB INTERNATIONAL 259
authors in their series report an experience of some 10 patients undergoing such
shunting and report only one early death from pulmonary sepsis and two other
cases of hepatic failure (one acutely and one as a slow progressive deterioration
requiring transplantation.) The addition of Hydroxyurea and Aspirin prevented
subsequent thrombosis although they are rightly concerned about the long term
outcome and possible further hepatic deterioration. Nevertheless, very nearly three
quarters of their patients were effectively salvaged in the short term by an urgent
shunt avoiding the need for transplantation and long term immunosuppression.
It seems likely therefore that most patients with non-malignant Budd-Chiari
Syndrome should be urgently considered for portal shunting. This has recetly been
our own approach when no cirrhosis exists and we have tried whenever possible to
avoid liver grafting and move at the earliest opportunity to porto-caval shunting if
medical therapy (hepatic vein dilatation or fibrinolysis) is proving ineffective. This
has clearly not been possible in the chronic Budd-Chiari patient with marked
fibrosis, cirrhosis and hypertension. A similar number of acute patients were
successfully shunted in our unit although usually using a meso-caval graft, success
has been achieved in all but one who subsequently encountered a thrombosis to the
graft.
The option of shunting however requires adequate hepatic reserve and the
urgent assessment of the underlying liver is a critical step. Biopsies frequently need
to be undertaken via the trans-jugular approach because of coagulation difficulties
and the risk of bleeding following percutaneous biopsy.
If success is to be achieved then early shunting requires an early diagnosis and the
essential clue perhaps to the early diagnosis is the disproportionate ascites in the
face of relatively good liver function. The diagnosis is then confirmed by ultrasound
of the hepatic veins followed by venography and trans-jugular biopsy. Urgent
studies are needed to determine the underlying cause of the hypercoagulable state
and bone marrow assessments looking for myeloproliferative disorders will usually
be required.
The prompt diagnosis of the acute Budd-Chiari Syndrome offers a prospect of
treatment perhaps initially by fibrinolysis or vein dilatation and then urgent
consideration for meso-caval shunting. Liver grafting will usually be reserved for
only those in whom shunting is followed by hepatic failure or in whom trans-jugular
histology shows advanced fibrotic/cirrhotic changes. The use of the meso-caval
shunt in no way comprises a subsequent liver transplant if that proves necessary
when a relatively simple ligation of the shunt can be made, and also avoids the
difficult enlarged caudate lobe seen in Budd-Chiari. Clearly however long term
follow-up is now needed for these patients to assess if satisfactory long term hepatic
function is achieved.
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